|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Lymphoma | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Lymphoma, T-Cell | |||||
| Lymphoma, T-Cell, Cutaneous | |||||
| Mycosis Fungoides | |||||
| Sezary Syndrome | |||||
| 3 | More general conditions related to this trial | ||||
| Immune System Diseases | |||||
| Immunoproliferative Disorders | |||||
| Lymphatic Diseases | |||||
| Lymphoma, Non-Hodgkin | |||||
| Lymphoproliferative Disorders | |||||
| Neoplasms | |||||
| Neoplasms by Histologic Type | |||||
| 4 | Interventions listed in this trial | ||||
| bexarotene | |||||
| methoxsalen | |||||
| UV light therapy | |||||
| 5 | More general drug interventions related to this trial | ||||
| Anticarcinogenic Agents | |||||
| Antineoplastic Agents | |||||
| Dermatologic Agents | |||||
| Pharmacologic Actions | |||||
| Photosensitizing Agents | |||||
| Physiological Effects of Drugs | |||||
| Protective Agents | |||||
| Radiation-Sensitizing Agents | |||||
| Therapeutic Uses | |||||
| 6 | Sponsors listed in this trial | ||||
| Millennix | |||||